ABSTRACT
Background Circulating immunometabolic biomarkers show promise for the diagnosis and treatment monitoring of tuberculosis (TB). However, biomarkers that can distinguish TB from nontuberculous mycobacteria (NTM) infections, latent tuberculosis infection (LTBI), and other lung diseases (ODx) have not been elucidated. This study utilized a multi-cohort, multi-omics approach combined with predictive modeling to identify, validate, and prioritize biomarkers for the diagnosis of active TB.
Methods Functional omics data were collected from two discovery cohorts (76 patients in the TB-NTM cohort and 72 patients in the TB-LTBI-ODx cohort) and one validation cohort (68 TB patients and 30 LTBI patients). An integrative multi-omics analysis was performed to identify the plasma multi-ome biosignatures. Machine learning-based predictive modeling was then applied to assess the performance of these biosignatures and prioritize the most promising candidates.
Results Conventional statistical analyses of immune profiling and metabolomics indicated minor differences between active TB and non-TB groups, whereas the lipidome showed significant alteration. Muti-omics integrative analysis identified three multi-ome biosignatures that could distinguish active TB from non-TB with promising performance, achieving area under the ROC curve (AUC) values of 0.7–0.9 across groups in both the discovery and validation cohorts. The lipid PC(14:0_22:6) emerged as the most important predictor for differentiating active TB from non-TB controls, consistently presenting at lower levels in the active TB group compared with counterparts. Further validation using two independent external datasets demonstrated AUCs of 0.77–1.00, confirming the biomarkers’ efficacy in distinguishing TB from other non-TB groups.
Conclusion Our integrative multi-omics reveals significant immunometabolic alteration in TB. Predictive modeling suggests lipids as promising biomarkers for TB-NTM differential diagnosis and TB-LTBI-ODx diagnosis. External validation further indicates PC(14:0_22:6) as a potential diagnostic marker candidate for TB.
Summary Our multi-cohort, multi-omics data integration and predictive modeling identified reliable biomarkers and highlighted the importance of circulating lipids for distinguishing tuberculosis (TB) from complex conditions with similar clinical manifestations, latent infections, and healthy individuals.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported in part by the National Research Foundation of Korea (NRF) grant funded by the Korean government (MSIT) (grant No. 2018R1A5A2021242) and in part by the National Research Foundation of Korean (NRF) grant funded by the Korean government (MSIT) (grant No. 2022R1C1C1009250). The funding organizations were not involved in the study design, data acquisition, data analysis, data interpretation, or the content presented in the manuscript.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board of Guro Hospital, Korea University (No. 2017GR0012) evaluated and approved the protocol for gathering patients' medical information and biospecimens for the analysis.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The data supporting this study's findings are available upon reasonable request.
